Therapeutic agents
OwnerJohn S. Shaw, William Bastaininventors
Life of this patent
Estimating the term…
Abstract
The use of compounds that are antagonists of the pain enhancing effects of E-type prostaglandins for the treatment or prevention of neuropathic pain are described. The use of a compound that is an antagonist of the pain enhancing effects of E-type prostaglandins in the production of a medicament for use in the treatment or prevention of neuropathic pain, and a method of treating or preventing neuropathic pain by administration of an effective amount of an antagonist of the pain enhancing effects of E-type prostaglandins to a warm blooded animal such as man are also described.
Claims7
The use of a compound that is an antagonist of the pain enhancing effects of E-type prostaglandins, or a pharmaceutically acceptable salt or an in vivo hydrolysable ester thereof, for the manufacture of a medicament for use in the treatment or prevention of neuropathic pain.
The use of a compound selected from:
- 6-[N-(2-benzyloxy-5-bromobenzyl)-N-ethylamino]pyridazine-3-carboxylic acid;
- 6-[N-(5-bromo-2-(2-methylprop-2-en-1-yloxy)benzyl)-N-ethylamino]pyridazine-3-carboxylic acid;
- N-propanesulphonyl-6-[N-(5-bromo-2-(cyclopropylmethoxy)benzyl)-N-ethylamino]pyridazine-3-carboxamide;
- N-(3,5-dimethylisoxazol-4-ylsulphonyl)-6-[n-(5-chloro-2-(2-methylpropoxy)benzyl)-nethylamino]pyridazine-3-carboxamide;
- and
- 6-[N-(5-bromo-2-(cyclopropylmethoxy)benzyl)-N-ethylamino]pyridazine-3-carboxylic acid;
- or a pharmaceutically acceptable salt or an in vivo hydrolysable ester thereof for the manufacture of a medicament for use in the treatment or prevention of neuropathic pain.
The use of N-propanesulphonyl-6-[N-(5-bromo-2-(cyclopropylmethoxy)benzyl)-N-ethylamino]pyridazine-3-carboxamide or a pharmaceutically acceptable salt or an in vivo hydrolysable ester thereof for the manufacture of a medicament for use in the treatment or prevention of neuropathic pain.
A pharmaceutical composition which comprises an antagonist of the pain enhancing effects of E-type prostaglandins or a pharmaceutically acceptable salt or an in vivo hydrolysable ester thereof, in association with a pharmaceutically acceptable excipient or carrier for the treatment or prevention of neuropathic pain.
A method of treating or preventing neuropathic pain in a warm blooded animal such as a human being requiring such treatment which comprises administering to said animal a therapeutically effective amount of an antagonist of the pain enhancing effects of E-type prostaglandins, or a pharmaceutically acceptable salt or an in vivo hydrolysable ester thereof.
A method of treating or preventing neuropathic pain in a warm blooded animal such as a human being requiring such treatment which comprises administering to said animal a therapeutically effective amount of a compound selected from:
- 6-[N-(2-benzyloxy-5-bromobenzyl)-N-ethylamino]pyridazine-3-carboxylic acid;
- 6-[N-(5-bromo-2-(2-methylprop-2-en-1-yloxy)benzyl)-N-ethylamino]pyridazine-3-carboxylic acid;
- N-propanesulphonyl-6-[N-(5-bromo-2-(cyclopropylmethoxy)benzyl)-N-ethylamino]pyridazine-3-carboxamide;
- N-(3,5-dimethylisoxazol-4-ylsulphonyl)-6-[N-(5-chloro-2-(2-methylpropoxy)benzyl)-N-ethylamino]pyridazine-3-carboxamide;
- and
- 6-[N-(5-bromo-2-(cyclopropylmethoxy)benzyl)-N-ethylamino]pyridazine-3-carboxylic acid;
- or a pharmaceutically acceptable salt or an in vivo hydrolysable ester thereof.
7 A method of treating or preventing neuropathic pain in a warm blooded animal such as a human being requiring such treatment which comprises administering to said animal a therapeutically effective amount of N-propanesulphonyl-6-[N-(5-bromo-2-(cyclopropylmethoxy)benzyl)-N-ethylamino]pyridazine-3-carboxamide, or a pharmaceutically acceptable salt or an in vivo hydrolysable ester thereof.
Dependencies are inferred from the claim text.